Development of artemisinin resistance in malaria therapy
- Publikationstyp:
- Zeitschriftenaufsatz
- Metadaten:
-
- Autoren
- Janine Nass
- Thomas Efferth
- Autoren-URL
- https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000482248300034&DestLinkType=FullRecord&DestApp=WOS_CPL
- DOI
- 10.1016/j.phrs.2019.104275
- eISSN
- 1096-1186
- Externe Identifier
- Clarivate Analytics Document Solution ID: IS6FS
- PubMed Identifier: 31100335
- ISSN
- 1043-6618
- Zeitschrift
- PHARMACOLOGICAL RESEARCH
- Schlüsselwörter
- Malaria
- Resistance
- Mutation
- Artemisinin
- Artemisinin combination therapy
- Artikelnummer
- ARTN 104275
- Datum der Veröffentlichung
- 2019
- Status
- Published
- Titel
- Development of artemisinin resistance in malaria therapy
- Sub types
- Review
- Ausgabe der Zeitschrift
- 146
Datenquelle: Web of Science (Lite)
- Andere Metadatenquellen:
-
- Autoren
- Janine Naß
- Thomas Efferth
- DOI
- 10.1016/j.phrs.2019.104275
- ISSN
- 1043-6618
- Zeitschrift
- Pharmacological Research
- Sprache
- en
- Artikelnummer
- 104275
- Paginierung
- 104275 - 104275
- Datum der Veröffentlichung
- 2019
- Status
- Published
- Herausgeber
- Elsevier BV
- Herausgeber URL
- http://dx.doi.org/10.1016/j.phrs.2019.104275
- Datum der Datenerfassung
- 2020
- Titel
- Development of artemisinin resistance in malaria therapy
- Ausgabe der Zeitschrift
- 146
Datenquelle: Crossref
- Abstract
- Malaria affects 200 million people worldwide. Today, the most successful treatments are artemisinin-based combination therapies (ACT). Resistance has already been described for the elder anti-malarials chloroquine, sulfadoxine-pyrimethamine and mefloquine. Unfortunately, over the last few years there has also been an emerging resistance to the successfully used drug artemisinin, especially in African and Asian countries. A systematic PubMed literature research was conducted for studies published between January 2002 and December 2018. Despite ACTs continue to be first line treatment, the number of studies is rising reporting on artemisinin resistance mutations. Most publications reported on kelch13 mutations (45 studies), the second most frequent mutations were found in pfmdr1 (32 studies). PfATPase6 mutations have been mainly studied in Asian countries (4 of 6 studies). Bearing this in mind, there is a pressing need to further examine the role and spread of mutations conferring artemisinin resistance. A further decline of treatment efficacy could result in increased rates of malaria-related deaths.
- Addresses
- Department of Pharmaceutical Biology, Institute of Biochemistry and Pharmacy, Johannes Gutenberg University, Staudinger Weg 5, 55128 Mainz, Germany.
- Autoren
- Janine Naß
- Thomas Efferth
- DOI
- 10.1016/j.phrs.2019.104275
- eISSN
- 1096-1186
- Externe Identifier
- PubMed Identifier: 31100335
- Funding acknowledgements
- Deutsche Forschungsgemeinschaft: DFG GRK 2015/1
- Open access
- false
- ISSN
- 1043-6618
- Zeitschrift
- Pharmacological research
- Schlüsselwörter
- Animals
- Humans
- Malaria
- Artemisinins
- Antimalarials
- Drug Resistance
- Mutation
- Polymorphism, Genetic
- Sprache
- eng
- Medium
- Print-Electronic
- Online publication date
- 2019
- Paginierung
- 104275
- Datum der Veröffentlichung
- 2019
- Status
- Published
- Datum der Datenerfassung
- 2019
- Titel
- Development of artemisinin resistance in malaria therapy.
- Sub types
- Research Support, Non-U.S. Gov't
- Systematic Review
- Journal Article
- Ausgabe der Zeitschrift
- 146
Datenquelle: Europe PubMed Central
- Abstract
- Malaria affects 200 million people worldwide. Today, the most successful treatments are artemisinin-based combination therapies (ACT). Resistance has already been described for the elder anti-malarials chloroquine, sulfadoxine-pyrimethamine and mefloquine. Unfortunately, over the last few years there has also been an emerging resistance to the successfully used drug artemisinin, especially in African and Asian countries. A systematic PubMed literature research was conducted for studies published between January 2002 and December 2018. Despite ACTs continue to be first line treatment, the number of studies is rising reporting on artemisinin resistance mutations. Most publications reported on kelch13 mutations (45 studies), the second most frequent mutations were found in pfmdr1 (32 studies). PfATPase6 mutations have been mainly studied in Asian countries (4 of 6 studies). Bearing this in mind, there is a pressing need to further examine the role and spread of mutations conferring artemisinin resistance. A further decline of treatment efficacy could result in increased rates of malaria-related deaths.
- Date of acceptance
- 2019
- Autoren
- Janine Naß
- Thomas Efferth
- Autoren-URL
- https://www.ncbi.nlm.nih.gov/pubmed/31100335
- DOI
- 10.1016/j.phrs.2019.104275
- eISSN
- 1096-1186
- Zeitschrift
- Pharmacol Res
- Schlüsselwörter
- Artemisinin
- Artemisinin combination therapy
- Malaria
- Mutation
- Resistance
- Animals
- Antimalarials
- Artemisinins
- Drug Resistance
- Humans
- Malaria
- Mutation
- Polymorphism, Genetic
- Sprache
- eng
- Country
- Netherlands
- Paginierung
- 104275
- PII
- S1043-6618(19)30474-8
- Datum der Veröffentlichung
- 2019
- Status
- Published
- Datum, an dem der Datensatz öffentlich gemacht wurde
- 2020
- Titel
- Development of artemisinin resistance in malaria therapy.
- Sub types
- Journal Article
- Research Support, Non-U.S. Gov't
- Systematic Review
- Ausgabe der Zeitschrift
- 146
Datenquelle: PubMed
- Beziehungen:
- Eigentum von